Caris Life Sciences, Inc. (CAI)
| Market Cap | 5.21B |
| Revenue (ttm) | 812.03M |
| Net Income (ttm) | -537.96M |
| Shares Out | 282.66M |
| EPS (ttm) | -3.22 |
| PE Ratio | n/a |
| Forward PE | 131.64 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,819,258 |
| Open | 19.85 |
| Previous Close | 19.93 |
| Day's Range | 18.39 - 19.85 |
| 52-Week Range | 16.28 - 42.50 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 30.91 (+67.63%) |
| Earnings Date | May 7, 2026 |
About CAI
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company’s molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecula... [Read more]
Financial Performance
In 2025, Caris Life Sciences's revenue was $812.03 million, an increase of 96.97% compared to the previous year's $412.26 million. Losses were -$537.96 million, 42.2% more than in 2024.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for CAI stock is "Strong Buy." The 12-month stock price target is $30.91, which is an increase of 67.63% from the latest price.
News
Caris Life Sciences Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw record revenue and profitability, driven by strong molecular profiling growth, improved ASPs, and expanding clinical volumes. 2026 guidance projects continued double-digit growth, positive cash flow, and major investments in early detection and commercial expansion.
Caris Life Sciences Transcript: 44th Annual J.P. Morgan Healthcare Conference
Strong financial results and cash position support aggressive investment in technology, commercial expansion, and a robust product pipeline. Early detection and MCED programs are advancing, with new partnerships and market penetration expected to drive growth in 2026 and beyond.
Caris Life Sciences Earnings Call Transcript: Q3 2025
Q3 2025 saw 113% revenue growth, record profitability, and margin expansion, driven by strong clinical profiling and higher ASPs. Guidance for FY25 was raised, with continued investment in early detection, MRD, and data platforms.
Caris Life Sciences Earnings Call Transcript: Q2 2025
Q2 2025 saw 81% revenue growth to $181.4M, driven by clinical and pharma segments, with gross margin up to 62.7%. Positive adjusted EBITDA and free cash flow were achieved, and FY 2025 revenue is guided to $675M–$685M, with strong growth expected in both volumes and ASPs.
Caris Life Sciences Files Registration Statement for Proposed Initial Public Offering
Caris Life Sciences, a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced...
Caris Life Sciences discloses rise in revenue in US IPO filing
Biotech company Caris Life Sciences filed its paperwork to go public in the U.S. on Friday as the stock market shows signs of recovery after tariff shocks.
Oncology precision medicine platform Caris Life Sciences files for an estimated $300 million IPO
Oncology precision medicine platform Caris Life Sciences files for an estimated $300 million IPO
Caris Life Sciences IPO Registration Document (S-1)
Caris Life Sciences has filed to go public with an IPO on the NASDAQ.